Neurothrombectomy Devices Market By Product Type (Clot Retrievers, Vascular Snares, Aspiration/Suction Devices, Others); By Technique (Mechanical Thrombectomy, Aspiration Thrombectomy, Combined Techniques); By End User (Hospitals, Ambulatory Surgical Centers (ASCs), Others); By Geography, Segment Revenue Estimation, Forecast, 2024–2032.

Neurothrombectomy Devices Market Size

The global neurothrombectomy devices market is projected to grow from $736.3 million in 2024 to $1,093.5 million by 2030, registering a CAGR of 6.8% during the forecast period. This steady growth reflects the rising demand for rapid, minimally invasive stroke interventions, coupled with expanding neurointerventional infrastructure across emerging markets & continuous innovation in device design and efficacy.

 

Neurothrombectomy Devices Market Dynamics:

Market Drivers

• Rising incidence of acute ischemic stroke (AIS)

Every year, 15 million people worldwide experience a stroke. Among them, 5 million succumb to the condition, while another 5 million live with stroke-related disabilities, affecting their families and communities. Stroke stands as the second leading cause of death globally, following ischemic heart disease. According to the Global Stroke Factsheet published in 2022, the lifetime risk of experiencing a stroke has risen by 50% over the past 17 years, with an estimated 1 in 4 people likely to suffer a stroke in their lifetime. A recent report from the World Stroke Organization-Lancet Neurology Commission highlights a rapid global increase in stroke cases. The findings suggest that stroke-related deaths worldwide could surge by 50% by 2050, with an estimated 10 million people losing their lives to stroke annually. According to a CDC study, self-reported stroke cases saw a 14.6% increase among individuals aged 18 to 44 and a 15.7% rise among those aged 45 to 64 between 2011–2013 and 2020–2022. Over the past decade, the management of acute ischemic stroke (AIS) has seen a remarkable evolution, primarily driven by advancements in endovascular thrombectomy (EVT). This progress has been further supported by improvements in thrombectomy devices, medical treatments, and optimized stroke workflows.

 

Figure: Distribution of ischemic stroke among patients (a) <45 and (b) >45 years of age.

 

Market Opportunities

• Role of AI in Neurothrombectomy Devices Market

Artificial Intelligence (AI) is playing an increasingly significant role in the field of neurothrombectomy for acute ischemic stroke, impacting every stage from diagnosis to post-procedure assessment. One of the most important contributions of AI lies in patient selection. AI-powered imaging tools such as Viz.ai, RapidAI, and Brainomix can quickly analyze CT or MR angiograms to detect large vessel occlusions (LVOs), estimate infarct core and penumbra volumes, and assess collateral circulation. AI also aids in the design and optimization of thrombectomy devices. Machine learning algorithms are used to simulate various anatomical and procedural scenarios, helping engineers design stent retrievers and aspiration catheters with improved flexibility, clot retrieval efficiency, and reduced risk of complications such as clot fragmentation or distal embolization.

 

Market Restraints

• Stringent Regulatory Requirements for Neurothrombectomy Devices

Neurothrombectomy devices are classified as high-risk, Class III medical devices, which means they are subject to the most stringent regulatory scrutiny globally. Regulatory bodies like the U.S. FDA, European Medicines Agency (EMA), and others require large-scale, multi-center clinical trials. These trials must demonstrate both safety and clinical effectiveness, especially for devices aimed at treating acute ischemic stroke. Trials are expensive and time-consuming, often taking 3–7 years from development to approval. In the U.S., most neurothrombectomy devices require Premarket Approval (PMA), not the simpler 510(k) pathway. Regulatory frameworks, especially in the U.S. and EU, are continuously updated to keep up with advancements in medical technology. Failure to meet compliance standards can lead to regulatory delays, rejections, or costly product recalls. This risk discourages smaller or emerging companies from entering the market.

 

Neurothrombectomy Devices Market: Recent Developments

• On July 10, 2024, Vesalio introduced the NeVa NET 4.0 mm device for treating acute ischemic stroke caused by large vessel occlusion, following the success of its 5.5 mm version. Both sizes feature a patented integrated micro-filter designed to prevent distal clot escape, a complication that affects up to 40% of neuro-thrombectomy procedures and can worsen patient outcomes. This filtration system enhances the device’s ability to retain clots effectively.

 

• On April 23, 2024, Penumbra, Inc. received FDA approval for Lightning Flash™ 2.0, an advanced computer-assisted vacuum thrombectomy (CAVT) system for venous thrombus removal and pulmonary emboli treatment. Featuring improved algorithms and novel catheter technology, it enhances speed, sensitivity, and navigation, enabling efficient clot removal with minimal blood loss.

 

• On February 2, 2023, Phenox Inc., a Wallaby Medical company, received FDA clearance for its Preset thrombectomy device to treat acute ischemic stroke in the U.S. Available in Europe for over a decade, the device is designed for quick deployment and ease of use, aiming to reduce disability in patients with large vessel occlusion who have undergone thrombolytic therapy.

 

Pipeline Report: Key Neurovascular Mechanical Thrombectomy Devices (As Of 2025)

Company	Device Name	Device Type	Development Stage	Key Differentiator / Notes
Anaconda Biomed	ANA5 Funnel Catheter	Aspiration Catheter	Clinical Trials (EU & US)	Funnel-based design for enhanced clot control and flow restoration. Targets first-pass success with novel aspiration strategy.
Vesalio	NeVa VS	Stent Retriever	CE Mark Granted; US Trials	Segmented architecture allowing clot integration along multiple vessel planes.
Route 92 Medical	FreeClimb 70, Tenzing 7	Aspiration + Access	US Clinical Trials (SUMMIT)	Proprietary access system paired with aspiration catheter designed to streamline navigation and improve outcomes.
Imperative Care	Zoom 88 Support Catheter	Adjunct Device	Limited Release / Early Adoption	Extra-large lumen for high-volume aspiration; strong support platform with minimal vessel trauma.
Rapid Medical	TIGERTRIEVER 13	Stent Retriever	CE Approved; US IDE Planned	Adjustable stent retriever with real-time control; already CE-approved for distal vessels.
Phenox GmbH	pRESET LUX	Stent Retriever	Clinical Evaluation (EU)	Coated version of pRESET with improved radiopacity and thrombus integration.
NeuroVasc Technologies	Envi-SR	Stent Retriever	US IDE in progress	Designed for improved trackability and thrombus engagement. Collaboration with Wego Group in China.
Silk Road Medical	ENROUTE Neuroprotection (expanded use)	Adjunct / Protection	Indication Expansion Trials	Undergoing trials for expanded use cases in anterior circulation strokes.

 

Neurothrombectomy Devices Market Segmentation: A Comprehensive Overview

By Product Type

• Clot Retrievers

• Vascular snares

• Aspiration/Suction Devices

• Others

 

By Technique

• Mechanical Thrombectomy

• Aspiration Thrombectomy

• Combined Techniques

 

By End User

• Hospitals

• Ambulatory Surgical Centers (ASCs)

• Others

 

By Region

• North America

• Asia-Pacific

• Europe

• Latin America

• Middle East Africa

 

Segmentation Analysis – Neurothrombectomy Devices Market

On the basis of product type, clot retrievers dominate the market accounting for approximately 56.4% of the neurothrombectomy devices market share. Clot retrievers, especially stent retrievers, are commonly used to extract blood clots from cerebral arteries in patients experiencing acute ischemic stroke. Trevo® NXT ProVue Retriever by Stryker is a next-generation stent retriever designed for use in mechanical thrombectomy procedures to restore blood flow in patients with acute ischemic stroke caused by large vessel occlusion.

 

Mechanical thrombectomy is currently the leading technique in the thrombectomy devices market, accounting for approximately 58.3% of the market share. This approach involves the physical removal of blood clots, typically using devices like stent retrievers, and is particularly effective in treating large vessel occlusions in acute ischemic stroke. Solitaire™ X Revascularization Device by Medtronic is a stent retriever used to remove blood clots from the brain in patients experiencing acute ischemic stroke. Solitaire™ X is widely used due to its strong clinical outcomes and ease of deployment in emergency stroke interventions.

 

Hospitals dominate the thrombectomy devices market with 70.3% share due to their advanced infrastructure, availability of specialized medical personnel & capacity to handle complex procedures. They are equipped with state-of-the-art imaging technologies & emergency departments, making them the preferred setting for acute ischemic stroke treatments. The high volume of procedures performed in hospitals contributes significantly to their market share.

 

Regional Analysis – Neurothrombectomy Devices Market

The North American market holds the largest share of the global neurothrombectomy devices market, accounting for approximately 41.9% in 2023. This dominance is largely driven by the high prevalence of ischemic strokes, advanced healthcare infrastructure & strong reimbursement systems. In 2021, stroke ranked as the fifth leading cause of death in the United States, with its financial burden on residents totaling approximately $56.2 billion over the 2019–2020 period. The presence of major device manufacturers such as Medtronic, Stryker & Penumbra further strengthens the market. Additionally, widespread awareness & access to cutting-edge stroke treatment centers contribute to North America's leadership position. The Paul Coverdell National Acute Stroke Program provides funding to states to assess, monitor, and enhance the quality of stroke patient care, aiming to reduce fatalities and long-term disabilities caused by stroke.

 

 

In the Asia-Pacific region, the market is expected to grow at the fastest rate over the forecast period showing significant growth potential.  Countries such as China, India & Japan are experiencing a surge in stroke cases due to aging populations, changing lifestyles, and increasing rates of hypertension and diabetes. Improvements in healthcare infrastructure, rising awareness about stroke treatment, and expanding access to mechanical thrombectomy procedures are fueling demand.

 

Key Players in the Neurothrombectomy Devices Market:

• Medtronic

• Stryker Corporation

• Penumbra Inc.

• Johnson & Johnson

• Terumo Corporation

• Acandis GmbH

• Phenox GmbH

• Vesalio

• AngioDynamics, Inc.

• Abbott Laboratories

 

Neurothrombectomy Devices Market Report Coverage

Report Attribute	Details
Forecast Period	2024 – 2032
Market Size Value in 2024	USD 736.3 Million
Revenue Forecast in 2030	USD 1,093.5 Million
Overall Growth Rate	CAGR of 6.8% (2024 – 2030)
Base Year for Estimation	2023
Historical Data	2017 – 2021
Unit	USD Million, CAGR (2024 – 2030)
Segmentation	By Product Type, By Technique, By End User, By Geography
By Product Type	Clot Retrievers, Vascular Snares, Aspiration/Suction Devices, Others
By Technique	Mechanical Thrombectomy, Aspiration Thrombectomy, Combined Techniques
By End User	Hospitals, Ambulatory Surgical Centers (ASCs), Others
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., Germany, China, Japan, India, UK, Brazil, etc.
Market Drivers	Rising incidence of stroke, technological advancements, growing awareness of early stroke treatment
Pricing and Purchase Options	Customization available upon request